Carlos Castaneda
Research Subjects
Research Interests
Carlos Castaneda has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Andres Azmitia Rugg
Centers for Disease Control and Prevention (CDC), Division of Global HIV & TB, Guatemala City 01016, Guatemala
1 shared publication - Benjamin Ryan Phelps
Office of HIV/AIDS United States Agency for International Development Washington DC USA
1 shared publication - Cristine Gutierrez
Centers for Disease Control and Prevention (CDC), Division of Global HIV & TB, Guatemala City, Guatemala
1 shared publication - Jose Rodas
Centers for Disease Control and Prevention (CDC), Division of Global HIV & TB, Guatemala City 01016, Guatemala
1 shared publication - Lissette Raquel Chang
Centers for Disease Control and Prevention (CDC), Division of Global HIV & TB, Guatemala City, Guatemala
1 shared publication - Nancy Aitcheson
Division of Infectious Diseases, Department of Medicine, University of Pennsylvania , Philadelphia, Pennsylvania
1 shared publication
Latest Publications
- Open Access
- 24 December 2025
- Published by MDPI AG in Tropical Medicine and Infectious Disease
- Vol. 11 (1) , 5
Analysis of Adolescent HIV Care Cascade Outcomes in PEPFAR-Supported Programs in Central America, October 2020–September 2024
To better understand recent adolescent (10–19 years) HIV trends in Central America, we analyzed routine data from countries supported by the United States President’s Emergency Plan for AIDS Relief (PEPFAR): Guatemala, El Salvador, Honduras, Panama, and Nicaragua, over the period from October 2020 to September 2024. Key PEPFAR indicators included HIV testing, HIV positivity rates, new treatment initiations, advanced HIV disease (AHD) at diagnosis, viral load coverage (VLC), viral load suppression (VLS), and multi-month dispensing (MMD) uptake for children and adolescents living with HIV (CALHIV) from 10–19 years of age. Since October 2020, the number of HIV tests conducted among adolescents has increased; however, the positivity rate has remained stable at approximately 2%. The number of adolescents initiating treatment increased by 21%. At the same time, VLS has shown steady regional improvement (from 73% to 90%), though VLC is a persistent challenge (80%). Treatment interruption rates have been relatively stable, fluctuating between 2% and 3%. Advanced HIV is high in adolescents new to treatment (34%), especially among females (40%), though cluster of differentiation 4 (CD4) testing at diagnosis has only been collected recently and coverage is not complete. The high prevalence of AHD among adolescents underscores the need to reinforce earlier and more targeted interventions for adolescents, especially in countries with greater HIV prevalence such as Panama and Guatemala.
- 24 December 2025
- Published by MDPI AG in Tropical Medicine and Infectious Disease
- Vol. 11 (1) , 5
Open AccessAnalysis of Adolescent HIV Care Cascade Outcomes in PEPFAR-Supported Programs in Central America, October 2020–September 2024
To better understand recent adolescent (10–19 years) HIV trends in Central America, we analyzed routine data from countries supported by the United States President’s Emergency Plan for AIDS Relief (PEPFAR): Guatemala, El Salvador, Honduras, Panama, and Nicaragua, over the period from October 2020 to September 2024. Key PEPFAR indicators included HIV testing, HIV positivity rates, new treatment initiations, advanced HIV disease (AHD) at diagnosis, viral load coverage (VLC), viral load suppression (VLS), and multi-month dispensing (MMD) uptake for children and adolescents living with HIV (CALHIV) from 10–19 years of age. Since October 2020, the number of HIV tests conducted among adolescents has increased; however, the positivity rate has remained stable at approximately 2%. The number of adolescents initiating treatment increased by 21%. At the same time, VLS has shown steady regional improvement (from 73% to 90%), though VLC is a persistent challenge (80%). Treatment interruption rates have been relatively stable, fluctuating between 2% and 3%. Advanced HIV is high in adolescents new to treatment (34%), especially among females (40%), though cluster of differentiation 4 (CD4) testing at diagnosis has only been collected recently and coverage is not complete. The high prevalence of AHD among adolescents underscores the need to reinforce earlier and more targeted interventions for adolescents, especially in countries with greater HIV prevalence such as Panama and Guatemala.